| Prev Close | 44.56 |
| Day Low/High | 44.26 / 45.17 |
| 52 Wk Low/High | 24.21 / 59.25 |
| Avg Volume | 5.65M |
Canopy Growth Corp. (CGC)
44.42
NYSE : Process Industries
| Exchange | NYSE |
| Shares Outstanding | 343.58M |
| Market Cap | 15.37B |
| EPS | -0.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Canopy Growth Now Has to be Considered the Leader in the Canadian Cannabis Space
CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
I Own Alphria Stock and the Big Q3 Loss Was Not a Surprise
The company has spent a lot of time and money trying to meet the supply needs of the recreational cannabis market.
2 Huge Earnings Reports I'm Watching This Week
A pair of earnings report this week will shed light on the future direction of two fast-growing companies in very different fields.
Not High on Pot
The action in pot stocks continues to be poor. I have a very small position in and even though the shares might be attractive over the long run, I won't be adding until I see some better price action. I have been cautious on the group for some time ...
Here's How to Trade Constellation Brands Stock
Oh, by the way, Constellation, for those who've forgotten, holds a 38% stake in Canopy Growth.
Constellation Brands Stock Can Still Run Despite Downgrade
There is certainly too much to ignore about STZ for the majority of analysts.
Constellation Brands Focuses on Beer, Tesla Deliveries Underwhelm
What I do know is that TSLA now faces a tumultuous uphill battle in order to meet its full year guidance.
2 Important Earnings Reports I'm Watching This Week
What to look for when Dave & Buster's and Constellation Brands report results.
Multi-State Cannabis Operators
The fact that everyone wants to know everyone's thoughts about Canopy Growth should tell you everything you want to know about CGC's current valuation and ownership. In fact, the Canadian LPs (Licensed Producers) are a tough game right now. These ar...
Up In Smoke?
The pot sector has been weak recently. I own a very small long position in which is -$1 to under $44/share (which was added to my Best Ideas List on January 2, 2019 at $27.75) As I mentioned I wasn't willing to pay up for recently and, in general, ...
2 Big Earnings Reports I'll Be Watching This Week
A huge week is coming up for these well-known stocks.
7 Indirect Stock Plays on the Cannabis Sector
Investors can gain exposure to the high-flying cannabis industry without taking on undue risks.
Canopy Growth
Yesterday I reestablished a long position in Canopy Growth - which has been on my Best Ideas List since early January, 2019. The shares are responding well to this news.
With Tilray, You Won't Win Any Valuation Arguments
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Further Bidding
Bidding further to the following longs (but slightly below the market): , and .
Tilray Is Not My Favorite Canadian Cannabis Stock
Apparently, this game is all about growth right now. It certainly is not about margins.
Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
New CGC Move
I am back long Canopy Growth (very) small (I bought the opening). Moved up my buy entry price in light of a market that seems to be more accepting of speculative stocks.
Stock of the Day - Tilray
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
Tilray Stock Lights Up as Partnerships Obscure Profitability Problem
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Chart of the Day: Vetting the Value of Cannabis Companies
Assessing Aurora and its peers, strictly on the numbers.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Peltz Is the Perfect Problem Solver for Aurora Cannabis
Peltz's addition should pacify a persistent critique of the company.
Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now
Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.
Buy Levels
Here are some of my individual buy levels of stocks that I want to add to or reestablish on weakness: * $157.50 * $1625 * $1150 * $42 * $55 * $46 * $46.50 * $182.50 * $31 * $40 * $23 * $65 * $16.75 * $35 * $27.75 * $60 * $95 * $48 * $87.50 Note: Lon...
